American Century Companies’s Intellia Therapeutics NTLA Stock Holding History

American Century Companies's NTLA Position: Q2 2026 in Review

American Century Companies increased its Intellia Therapeutics (NTLA) stake by 15% in Q2 2026, buying an estimated $430K and bringing the position to 239,016 shares worth $4.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

American Century Companies first reported a position in NTLA in Q2 2017 and has held it in 22 quarters since. The position peaked at $15M in Q3 2022. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

• American Century Companies held 239,016 shares of Intellia Therapeutics worth $4.04M as of Q2 2026.
• American Century Companies bought 30,715 Intellia Therapeutics shares in Q2 2026, an estimated $430K.
• Intellia Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #1966 holding.
• American Century Companies first reported a position in Intellia Therapeutics in Q2 2017 and has held it in 22 quarters since.
• American Century Companies's Intellia Therapeutics position peaked at $15M in Q3 2022.
• 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.